e-Therapeutics PLC's (LON:ETX) Alan Whitmore joins Proactive London's Katie Pilbeam to explain the results of experimental testing on compounds for the treatment of coronavirus (COVID-19) identified using its Network-driven Drug Discovery (NDD) platform.
Whitmore explains that when they analysed the latest data, the systemic inflammatory response syndrome (SIRS) and of data sets from human cells infected with SARS-CoV-2, the virus that causes COVID-19, there was an overlap important to both the virus and the hyperinflammatory response.